IFOBT TF Only IFOBT Only TF BOTH EITHER P valuea Positive patientsb 86(42.8) 93(46.3) 37(18.4) 44(21.9) 49(24.4) 130(64.7) 0.000 Sensitivityc 　 　 　 　 　 　 　 All advanced adenomas and cancer(68) 38(55.9) 40(58.8) 13(19.1) 15(22.1) 25(36.8) 53(77.9) 0.006 Cancer(21) 12(57.1) 16(76.2) 2(9.5) 6(28.6) 10(47.6) 18(85.7) 0.040 Dukes A/B Cancer(9) 4(44.4) 6(66.7) 1(11.1) 3(33.3) 3(33.3) 7(77.8) 0.147 Dukes C/D Cancer(12) 8(66.7) 10(83.3) 1(8.3) 3(25.0) 7(58.3) 11(91.7) 0.142 Advanced adnomas(47) 26(55.3) 24(51.1) 11(23.4) 9(19.1) 15(31.9) 35(74.5) 0.052 Advanced adenoma ≥10 mm(36) 21(58.3) 16(44.4) 10(27.8) 5(13.9) 11(30.6) 26(72.2) 0.216 Advanced adenoma <10 mm(11)d 5(45.5) 8(72.7) 1(9.1) 4(36.4) 4(36.4) 9(81.8) 0.076 Specificitye 　 　 　 　 　 　 　 All advanced adenomas and cancer(68) 48(63.9) 53(60.2) 24(82.0) 29(78.2) 24(82.0) 77(42.1) 0.005 Cancer(21) 74(58.9) 77(57.2) 35(80.6) 38(78.9) 39(78.3) 112(37.8) 0.005 Negative predictive valuef               All advanced adenomas and cancer(68) 85(73.9) 80(74.1) 109(66.5) 104(66.2) 109(71.7) 56(78.9) 0.443 Cancer(21) 106(92.2) 103(95.4) 145(88.4) 142(90.4) 141(92.8) 68(95.8) 0.332 Positive predictive valueg               All advanced adenomas and cancer(68) 38(44.2) 40(43.0) 13(35.1) 15(34.1) 25(51.0) 53(40.8) 0.619 Cancer(21) 12(14.0) 16(17.2) 2(5.4) 6(13.6) 10(20.4) 18(13.8) 0.982 Dukes A/B Cancer(9) 4(4.7) 6(6.5) 1(2.7) 3(6.8) 3(6.1) 7(5.4) 0.810 Dukes C/D Cancer(12) 8(9.3) 10(10.8) 1(2.7) 3(6.8) 7(14.3) 11(8.5) 0.831 Advanced adenomas(47) 26(30.2) 24(25.8) 11(29.7) 9(20.5) 15(30.6) 35(26.9) 0.597 Advanced adenoma≥10 mm(36) 21(24.4) 16(17.2) 10(27.0) 5(11.4) 11(22.4) 26(20.0) 0.441 Advanced adenoma<10 mm(11) 5(5.8) 8(8.6) 1(2.7) 4(9.1) 4(8.2) 9(6.9) 0.746 aTF combined with IFOBT (Either/or) vs IFOBT alone. bNumbers in parenthesis are the rates calculated by number of positive patients divided by the number of total participants. cSensitivity is the number of true positives relative to the number of persons with lesions. d≥1 villous adenoma or adenoma with high-grade dysplasia and no adenomas ≥10mm eSpecificity is the number of true negatives relative to the number of persons without lesions. Numbers presented are the number of false-positives per group. fNPV is the number of true negatives relative to the number of persons with negative tests. Numbers presented are the number of true-negatives per group. gPPV is the number of true positives relative to the number of total positive patients.

Table 4: Results of IFOBT and TF, either alone or combination, and subsequent colonoscopic findings in symptomatic population (201 participants), n(%).